Afstyla (Lonoctocog Alfa)

Afstyla is a coagulation factor VIII replacement therapy used to manage bleeding episodes in hemophilia A. This intravenous medication helps restore clotting function, offering support for routine and on-demand treatment.

Afstyla is primarily used for the treatment and prevention of bleeding episodes in individuals with hemophilia A, a genetic disorder characterized by a deficiency in clotting factor VIII. It is designed to replace the missing factor VIII, thereby aiding in the clotting process. This medication can be used both for routine prophylaxis and to manage acute bleeding events.

Afstyla works by replacing the missing clotting factor VIII in the blood, which helps to form a stable blood clot. This can reduce the frequency and severity of bleeding episodes in individuals with hemophilia A. Common effects may include improved clotting function and reduced bleeding risk during and after procedures.

Afstyla should be administered under the supervision of a healthcare professional. It is important to monitor for any signs of allergic reactions or adverse effects. Patients should inform their healthcare provider about any pre-existing conditions or medications they are taking before starting treatment with Afstyla.

Afstyla may interact with certain medications, particularly those that affect blood clotting. It is advisable to consult with a healthcare provider before combining Afstyla with other treatments. Additionally, patients should be cautious when using Afstyla alongside medications that may increase the risk of bleeding.